Qualitest Recalls Disulfiram Tablets Due to Dissolution Failure
Qualitest Pharmaceuticals is recalling 2,016 bottles of Disulfiram tablets because one lot failed routine stability testing for dissolution specifications.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which indicates the product is not likely to cause adverse health consequences. The hazard is a quality control failure (dissolution) rather than a direct safety threat like contamination or mislabeling of a critical allergen.
Plain-English summary
Qualitest Pharmaceuticals is voluntarily recalling 2,016 bottles of Disulfiram tablets, USP, 500 mg, 100-count bottles. The affected product is prescription-only and was distributed nationwide. The specific lot numbers involved are T142A14A, T143A14A, and T144A14A, all with an expiration date of 01/16.
The recall was initiated after routine stability testing at the 12-month time point revealed that one product lot was out of specification for dissolution. This means the tablets may not dissolve at the required rate, potentially affecting the medication's performance.
Consumers and healthcare providers should check their inventory for the specific lot numbers and expiration dates listed above. If the product matches the recalled description, it should be discontinued and returned to the supplier or disposed of according to local regulations. No adverse health effects have been reported in connection with this recall.
The recalled product
- Product
- Disulfiram tablets, USP, 500 mg, 100-count bottles, Rx only, Manufactured for and by Qualitest Pharmaceuticals 130 Vintage Drive Huntsville, AL 35811. NDC 0603-3432-21.
- Manufacturer
- Qualitest Pharmaceuticals
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 2,016
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #: T142A14A
- T143A14A
- T144A14A
- Exp 01/16
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Qualitest Pharmaceuticals
See all →- LowQualitest Recalls Allopurinol Tablets Due to Oversized and Discolored Appearance
FDA (Drugs) · 2015-09-09
- LowQualitest Recalls HydrOXYzine Tablets Due to Unreadable Identification Codes
FDA (Drugs) · 2015-07-22
- LowQualitest Recalls Promethazine VC With Codeine Syrup Due to Impurity
FDA (Drugs) · 2015-04-15
- ModerateQualitest Recalls Promethazine DM Syrup Due to Plastic Particulates
FDA (Drugs) · 2015-03-18
- ModerateQualitest Recalls Amlodipine Besylate Tablets Due to Oversized Size
FDA (Drugs) · 2015-03-11
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17